Despite KKR's exit, Warburg Pincus is reportedly continuing efforts to complete a deal independently. Gerresheimer disclosed in February that it had entered early-stage, informal discussions with private equity investors regarding a potential sale. However, no binding agreement has been reached to date. The deal, if revived, would mark a notable transaction in the European healthcare and life sciences space, a sector that remains of high interest to private equity investors amid continued consolidation and innovation in pharmaceutical infrastructure. Subscribe to our Newsletter to increase your edge. Don't worry about the news anymore, through our newsletter you'll receive weekly access to what is happening. Join 120,000 other PE professionals today.
learn more
